-
Nat Biotechnol: Scientists are expected to develop a new potential anti-cancer drug
Time of Update: 2023-01-05
1038/s41587-022-01510-z The therapeutic potential of recombinant cytokines has always been limited by the serious side effects of systemic administration; Recently, a study entitled "A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy" published in the international journal Nature Biotechnology, scientists from the University of Washington School of Medicine and other institutions have shown that When an experimental cancer drug is split in two, the molecule may become safer and more effective.
-
2023 China Protective Materials and Disinfection Products Fair
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];2023 China Public Health and Epidemic Prevention Materials Exhibition and 86th Drug Fair May 9-11, 2023 Qingdao World Expo City International Exhibition Center Same place at the same time The 86th National Drug Fair, China International Health and Nutrition Expo (NHNE), Traditional Chinese Medicine Expo, China Pharmacy Procurement and Supply Expo, 2023 China Health and Nutrition Raw Materials/Packaging/Equipment Exhibition (NHi) Booth reservation, please inquire!
-
At the end of the year, pharmaceutical companies are busy "breaking wrists", selling and adjusting R&D pipelines...
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];At the end of each year, the pharmaceutical industry is always busy, especially in the context of the intensification of changes in the pharmaceutical market, many pharmaceutical companies are busy selling and adjusting their R&D pipelines to better cope with the challenges.
-
Well-known pharmaceutical companies are heavily fined for monopoly! Malicious price gouging will meet the regulator's heavy punch!
Time of Update: 2023-01-05
In order to curb and crack down on the monopolistic behavior of pharmaceutical companies such as Jinyao Pharmaceutical, the regulatory authorities have been focusing on anti-monopoly investigations in the pharmaceutical field, severely punishing monopoly supply cuts and price increases: In February 2017, the State Administration for Industry and Commerce issued a fine of 2.
-
Regarding matters related to the establishment of Shijiazhuang Air Port as a port for the import of medicines
Time of Update: 2023-01-05
Provincial Institute of DrugMedical Device Annex: Shijiazhuang Market Supervision Administration's special seal for drug import filing General Office of the General Administration of Customs of the State Food and Drug Administration November 15, 2022
-
The fair and orderly pharmaceutical equipment market order needs to be jointly maintained by enterprises
Time of Update: 2023-01-05
In mid-November this year, the Office of the National Leading Group for Cracking Down on Intellectual Property Rights Infringement and the Manufacturing and Sale of Counterfeit and Shoddy Goods and the State Administration for Market Regulation led a nationwide unified destruction of infringing and shoddy goods, with the participation of 18 provinces (autonomous regions and municipalities) and simultaneous destruction.
-
Tianjin Market Supervision Commission issued a medical beauty advertising reminder
Time of Update: 2023-01-05
(End) The reporter learned from the Tianjin Market Supervision Commission on the 22nd that recently, in order to standardize the release of medical beauty advertisements and protect the legitimate rights and interests of consumers, the Tianjin Market Supervision and Administration Commission has made the following key reminders in accordance with the "Advertising Law of the People's Republic of China" and "Medical Advertising Management Measures" and other laws and regulations: 1.
-
The peak sales season of Chinese medicine is also the peak season for processing! Pharmaceutical equipment empowers development
Time of Update: 2023-01-05
After entering the winter, the seasonal flu is high, and traditional Chinese medicine ushered in the sales season, it is understood that recently including forsythia, silver flower, banlan root, dand
-
Countdown to the live broadcast of the exhibition! This year's 100th China Electronics Fair is very "new"
Time of Update: 2023-01-05
【Pharmaceutical Network Exhibition Report】Entering a new era, China has changed from pursuing high-speed development to pursuing high-quality development. Among them, the electronic information indust
-
NEW CHANGE! In these cases of post-listing changes, please cancel the filing in time
Time of Update: 2023-01-05
The author has compiled the latest developments in the recent post-listing change supporting policies of various provincial bureaus in the pharmaceutical industry, one of the very important news is: on November 17, 2022, the Shandong Provincial Drug Administration issued the "Notice on Public Solicitation of Opinions on the Implementation Rules for the Administration of Post-marketing Changes to Drugs in Shandong Province", the most important of which is the addition of Article 8 to cancel the filing.
-
One more port of import for medicines! Chinese medicine, chemical medicine, etc. can be imported
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];On November 15, the State Food and Drug Administration issued the Notice of the General Office of the General Administration of Customs of the State Food and Drug Administration on Matters Related to the Establishment of Shijiazhuang Air Port as a Drug Import Port, which showed that after approval, it was agreed to add Shijiazhuang Air Port as a drug import port.
-
Sail Bravely and Perseverance 2022 Autumn Exhibition Ended Successfully See you next year!
Time of Update: 2023-01-05
【Pharmaceutical Network Exhibition Report】On November 21, the 2022 Television Conference Autumn Exhibition hosted by Instrument Network ended successfully, and since its launch on November 15, the liv
-
39 listed companies disclosed their 2022 annual report performance forecasts, focusing on electronics, medicine and other fields
Time of Update: 2023-01-05
04% year-on-year Dongxing Medical announced on November 10 that it expects operating income from January to December 2022 to be 485 million yuan to 515 million yuan, an increase of 8.
-
Local ADC inventory: HER2, TROP2 are the most crowded, Hengrui, CSPC, Kelun, East China Medicine and other in-depth layout!
Time of Update: 2023-01-05
(Incomplete statistics, if there is any error or omission of information, welcome to leave a message) Target homogenization is seriousHER2 and TROP2 are the most crowded Target clustering is a common phenomenon of global research and development, and this phenomenon is even more so in domestic ADC new drugs, according to statistics, 22 ADC drugs targeting the "number one target" HER2 have been announced in China, accounting for 26% of all products.
-
120 medical device companies released three quarterly reports, more than ninety percent earned!
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];Data show that as of October 31, 120 medical device companies have released three quarterly reports, and more than ninety percent have achieved double growth in revenue and net profit.
-
The domestic AI pharmaceutical field is hot, attracting nearly 10 billion yuan in 2021
Time of Update: 2023-01-01
AI pharmaceuticals are different from traditional pharmaceuticals and are expected to break the dilemma that the average cost of new drug research and development exceeds US$1 billion and the R&D cycle is greater than 10 years, so it is highly expected by the industry.
-
The collection of drugs into pharmacies has accelerated, and the retail industry has ushered in more opportunities
Time of Update: 2023-01-01
According to media reports, since the beginning of this year, 161 designated retail pharmacies in Xuzhou, Jiangsu Province have passed the acceptance inspection, covering 150 townships (streets) in the city, including 138 chain retail pharmacies and 23 single retail pharmacies.
-
Tens of billions of yuan ophthalmic treatment market, domestic pharmaceutical companies continue to have good news
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];Ophthalmic drugs have now become a golden track for new drug research and development, and in recent years, the domestic ophthalmic drug market has maintained steady growth.
-
New drugs for malaria! Novartis' novel combination therapy with MMV ganaplacide/lumefantrine-SDF will enter Phase 3 clinical development!
Time of Update: 2023-01-01
Nov. 25, 2022 /Biovalley BIOON/ -- Novartis and the non-profit organization Medicines for Malaria Venture (MMV) have jointly announced that the two parties have decided to advance ganaplacide/lumefantrine-solid dispersible (SDF) to Phase 3 clinical development as the threat of resistance to current antimalarial therapies increases.
-
Pharmaceutical companies are overbearing to eat KRAS G12C inhibitors, and a new round of tumor new drug racing has begun fiercely
Time of Update: 2023-01-01
In addition to the marketed Sotorasib, Mirati Therapeutics' Adagrasib (MRTX849) has submitted a new drug application to the US FDA; JDQ443 developed by Novartis is in phase III clinical trials for non-small cell lung cancer.
